- 
MRNA most of the people are familiar with the vaccine stocks from pandemic fiasco.
- This company is beaten down to the ground and has low market cap as compared to other biopharma stocks.
- 2025 would be easier for merger and acquisition which will be good for moderna as it might get acquired by other biopharma companies to accelerate their growth.
- Bird Flu in the US and rise of HPMV in China will create an upward pressure in terms of demand of these stocks. Monitor the news for HPMV as it seems it is more severe than the COVID
MRNA most of the people are familiar with the vaccine stocks from pandemic fiasco. - This company is beaten down to the ground and has low market cap as compared to other biopharma stocks.
- 2025 would be easier for merger and acquisition which will be good for moderna as it might get acquired by other biopharma companies to accelerate their growth.
- Bird Flu in the US and rise of HPMV in China will create an upward pressure in terms of demand of these stocks. Monitor the news for HPMV as it seems it is more severe than the COVID
Trade fermée: ordre d’arrêt atteint
closed after gap down
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.